Repare Therapeutics Inc. announced the appointment of Philip Herman as its EVP Commercial & New Product Development. Mr. Herman joins Repare from Y-mAbs Therapeutics, where he served as Chief Commercial Officer and led the successful launch of DANYELZA® (naxitamab).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.02 USD | +13.88% | +24.46% | -44.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.93% | 150M | |
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |
- Stock Market
- Equities
- RPTX Stock
- News Repare Therapeutics Inc.
- Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development